IP Library Granted Patent US 7,981,923
Granted Patent B2
US 7,981,923 · App. 12/694,033 · Granted Jul 19, 2011

Tetralin and indane derivatives and uses thereof

Assignee: Roche Palo Alto LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,923
App. No.
12/694,033
Granted
Jul 19, 2011
Kind
B2
Abstract

Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.

Claims (55)

1. A compound of formula II:

or a pharmaceutical salt thereof,

wherein:

m is from 0 to 3;

n is from 1 to 3;

Ar is optionally substituted aryl or optionally substituted heteroaryl;

each R 1 is independently halo, alkyl, haloalkyl, alkoxy, hydroxy, heteroalkyl, cyano, —S(O) t —R a , —C(═O)—NR b R c , —SO 2 —NR b R c , —N(R d )—C(═O)—R e , or —C(═O)—R e , where t is from 0 to 2, R a , R b , R c , R d and R e each independently is hydrogen or alkyl, and R f is hydrogen, alkyl, alkoxy or hydroxy;

R 2 is hydrogen or alkyl; and

R 4 is alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl or —(CH 2 ) p —NR 5 R 6 , wherein

p is 0 or 1;

R 5 is hydrogen or alkyl; and

R 6 is hydrogen, alkyl, guanidinyl, hydroxyalkyl or alkoxyalkyl,

provided that:

when m is O and R 4 is —NHCH 3 , —N(CH 3 ) 2 , —CH 2 NH 2 , —CH 2 NHCH 3 , —CH 2 N(CH 3 ) 2 , or —CH 2 OH, then Ar is not 3-fluoro-phenyl;

when m is O and R 4 is —NH 2 or guanidinyl, then Ar is not phenyl or 3-fluoro-phenyl;

when m is 1, R 1 is fluoro at the 8-position of the tetralin ring system, and R 4 is methyl, then Ar is not phenyl,

when m is 0 and R 4 is methyl, then Ar is not 3-fluoro-phenyl or indol-3-yl; and

when m is 0 and R 4 is methoxy or ethoxy, then Ar is not 3-fluoro-phenyl or 2-fluoro-phenyl.

2. The compound of claim 1 , wherein said compound is of the formula Va or Vb:

or a pharmaceutical salt thereof,

wherein:

s is from 0 to 4;

each R 7 is independently halo, alkyl, alkoxy, haloalkyl, heteroalkyl, cyano, —S(O) r —R a , —C(═O)—NR b R c , —SO 2 —NR b R c , —N(R d )—C(═O)—R e , or —C(═O)—R e , where r is from 0 to 2, R a , R b , R c and R d each independently is hydrogen or alkyl, and R e is hydrogen, alkyl, alkoxy or hydroxy; and

m, n, R 1 , R 2 and R 4 are as recited in claim 1 .

3. The compound of claim 2 , wherein m is 0 or 1, and R 1 is halo.

4. The compound of claim 3 , wherein R 1 is fluoro.

5. The compound of claim 3 , wherein R 1 is located at the 5- or 8-position of the tetralin ring system.

6. The compound of claim 2 , wherein m is 1, R 1 is fluoro, n is 1, s is 1, and R 7 is halo.

7. The compound of claim 6 , wherein R 7 is fluoro.

8. The compound of claim 7 , wherein R 1 is 3-fluoro.

9. The compound of claim 2 , wherein said compound is selected from the group consisting of:

N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-2,2-dimethyl-propionamide;

N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-2-hydroxy-2-methyl-propionamide;

N-(6-Benzenesulfonyl-8-fluoro-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-isobutyramide;

N-(6-Benzenesulfonyl-8-fluoro-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-propionamide;

N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-2-methoxy-acetamide;

N-(6-Benzenesulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-acetamide;

N-[5-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-acetamide;

N-[5-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-2-hydroxy-acetamide;

N-(6-Benzenesulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-2-hydroxy-acetamide;

[5-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea;

2-Hydroxy-N-[6-(1H-pyrrole-3-sulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-acetamide;

[8-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea;

(6-Benzenesulfonyl-8-fluoro-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-urea;

[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea; and

N-[8-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-2-hydroxy-acetamide.

10. The compound of claim 9 , wherein said compound is selected from the group consisting of:

[5-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea;

[8-Fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea;

(6-Benzenesulfonyl-8-fluoro-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-urea; and

[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea.

11. The compound of claim 10 , wherein said compound is [5-fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea.

12. The compound of claim 10 , wherein said compound is [8-fluoro-6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea.

13. The compound of claim 10 , wherein said compound is (6-benzenesulfonyl-8-fluoro-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-urea.

14. The compound of claim 10 , wherein said compound is [6-(3-fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea.

Continuity (4)
Division 11820712 · Jun 20, 2007
Provisional Application 60815312 · Jun 20, 2006
Provisional Application 61075277 · Jun 24, 2008
Related Publication 20100130742A1 · May 27, 2010